Completed PHASE3 INTERVENTIONAL 2-arm NCT00129402

Effects of Ezetimibe With Simvastatin in the Therapy of Adolescents With HeFH (Study P02579)

Efficacy, Safety, and Tolerability of Ezetimibe in Coadministration With Simvastatin in the Therapy of Adolescents With Heterozygous Familial Hypercholesterolemia

Sponsor: Merck Sharp & Dohme LLC

Conditions Hypercholesterolemia

Interventions ezetimibe with simvastatin simvastatin

Updated 8 times since 2017 Last updated: Feb 4, 2022 Started: Aug 31, 2005 Primary completion: Jun 30, 2007 Completion: Jun 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Hypercholesterolemia and is currently completed. Merck Sharp & Dohme LLC leads this study, which shows 8 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jun 2022 — Jul 2024 [monthly]

Completed PHASE3
Mar 2022 — Jun 2022 [monthly]

Completed PHASE3
Jan 2021 — Mar 2022 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Aug 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merck Sharp & Dohme LLC
Organon and Co

Data source: Organon and Co

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.